In this observational study researchers want to learn more about the safety of drug Jivi over a long period of time. Jivi (generic name: Damoctocog alfa pegol) is an approved blood clotting Factor VIII (FVIII) medication for the treatment of hemophilia A (bleeding disorder resulting from a lack of FVIII). It is manufactured via recombinant technology and has an extended half-live, i.e. it will stay longer in the body than other FVIII products. Therefore Jivi acts longer in the body which reduces the frequency of drug injections. This study will enroll previously treated patients with hemophilia A who are receiving Jivi regularly at their treating doctors to prevent bleeding. Observation for each patient will last for at least 4 years, and medical data will be collected during patients' routine visits at their treating doctors.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with safety events
Timeframe: At least 4 years
Duration of safety events
Timeframe: At least 4 years
Number of participants with safety events leading to a change of treatment
Timeframe: At least 4 years
Number of participants with safety events per intensity
Timeframe: At least 4 years
Number of participants with safety events with outcome of death
Timeframe: At least 4 years
Number of participants with safety events related to inhibitor development
Timeframe: At least 4 years